Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 8/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CPB1 | P15086 | 1/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12662749 | 0.79 | CPB2 (0.50) | ALDH1A1MTNR1AACACBCPB2LMNA | |
| SCHEMBL12662747 | 0.78 | CPB2 (0.48) | ALDH1A1MTNR1AACACBCPB2LMNA | |
| SCHEMBL15065061 | 0.73 | CPB2 (0.47) | ALDH1A1MTNR1AACACBCPB2LMNA | |
| SCHEMBL13256665 | 0.72 | CPB2 (0.41) | ALDH1A1MTNR1AACACBMEN1KMT2A | |
| SCHEMBL17665491 | 0.72 | MEN1 (0.42) | ALDH1A1MEN1KMT2ACPB2LMNA | |
| SCHEMBL13256666 | 0.71 | PIK3CG (0.49) | MTNR1AACACBCPB2CPB1 | |
| SCHEMBL4388519 | 0.70 | CYP2C9 (0.51) | ALDH1A1MTNR1AACACBLMNAMTNR1B | |
| SCHEMBL1025097 | 0.69 | RAB9A (0.52) | ALDH1A1RAB9A | |
| SCHEMBL2027274 | 0.68 | ALDH1A1 (0.50) | ALDH1A1LMNA | |
| SCHEMBL31483145 | 0.67 | CPB2 (0.52) | CPB2CPB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2017-11-16 | — | — | US | disclosed |
| WO-2016058704-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | SCV GMBH (DE) | 2016-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170327520-A1 | CONJUGATED BISPHOSPHONATES FOR THE DIAGNOSIS AND THERAPY OF BONE DISEASES | PTH1R, VDR, MEN1 | ALDH1A1 4006/4885MTNR1A 1985/4885ACACB 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.